Prelude therapeutics reports full year 2024 financial results and provides program outlook for 2025

Prt3789 has demonstrated clinical proof-of-concept that selectively degrading smarca2 is generally safe and has monotherapy anti-tumor activity in patients with smarca4-deficient, non-small cell lung (nsclc), gastric and esophageal cancer

PRLD Ratings Summary

PRLD Quant Ranking